Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Vanda Pharmaceuticals

DB:VM4
Snowflake Description

Very undervalued with outstanding track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
VM4
DB
$551M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address unmet medical needs and improve the lives of patients. The last earnings update was 39 days ago. More info.


Add to Portfolio Compare Print
  • Vanda Pharmaceuticals has significant price volatility in the past 3 months.
VM4 Share Price and Events
7 Day Returns
20.6%
DB:VM4
-0.7%
DE Biotechs
-0.6%
DE Market
1 Year Returns
-39.6%
DB:VM4
-13.2%
DE Biotechs
-20.9%
DE Market
VM4 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Vanda Pharmaceuticals (VM4) 20.6% 3.1% -30.4% -39.6% -20% 14.3%
DE Biotechs -0.7% -8.2% -21% -13.2% 13.2% -11.8%
DE Market -0.6% -18.6% -26.2% -20.9% -25.8% -31.8%
1 Year Return vs Industry and Market
  • VM4 underperformed the Biotechs industry which returned -13.2% over the past year.
  • VM4 underperformed the Market in Germany which returned -20.9% over the past year.
Price Volatility
VM4
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Vanda Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Vanda Pharmaceuticals to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Vanda Pharmaceuticals.

DB:VM4 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 4 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 5.8%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:VM4
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 5.4%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.19
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.188 (1 + (1- 21%) (2.65%))
1.143
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.14
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (1.143 * 5.44%)
5.83%

Discounted Cash Flow Calculation for DB:VM4 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Vanda Pharmaceuticals is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

DB:VM4 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 5.83%)
2020 57.06 Est @ 27.47% 53.92
2021 67.96 Est @ 19.11% 60.69
2022 76.97 Est @ 13.26% 64.95
2023 84.03 Est @ 9.16% 67.00
2024 89.32 Est @ 6.3% 67.30
2025 93.15 Est @ 4.29% 66.32
2026 95.84 Est @ 2.89% 64.48
2027 97.67 Est @ 1.9% 62.09
2028 98.86 Est @ 1.22% 59.39
2029 99.58 Est @ 0.73% 56.53
Present value of next 10 years cash flows $622.00
DB:VM4 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $99.58 × (1 + -0.39%) ÷ (5.83% – -0.39%)
$1,595.92
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $1,595.92 ÷ (1 + 5.83%)10
$905.96
DB:VM4 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $622.00 + $905.96
$1,527.96
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $1,527.96 / 53.65
$28.48
DB:VM4 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:VM4 represents 0.96743x of NasdaqGM:VNDA
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.96743x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 28.48 x 0.96743
€27.55
Value per share (EUR) From above. €27.55
Current discount Discount to share price of €9.95
= -1 x (€9.95 - €27.55) / €27.55
63.9%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Vanda Pharmaceuticals is available for.
Intrinsic value
>50%
Share price is €9.95 vs Future cash flow value of €27.55
Current Discount Checks
For Vanda Pharmaceuticals to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Vanda Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Vanda Pharmaceuticals's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Vanda Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Vanda Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:VM4 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $2.17
NasdaqGM:VNDA Share Price ** NasdaqGM (2020-04-03) in USD $10.29
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 40.67x
Germany Market PE Ratio Median Figure of 401 Publicly-Listed Companies 16.57x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Vanda Pharmaceuticals.

DB:VM4 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:VNDA Share Price ÷ EPS (both in USD)

= 10.29 ÷ 2.17

4.73x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Vanda Pharmaceuticals is good value based on earnings compared to the Europe Biotechs industry average.
  • Vanda Pharmaceuticals is good value based on earnings compared to the Germany market.
Price based on expected Growth
Does Vanda Pharmaceuticals's expected growth come at a high price?
Raw Data
DB:VM4 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 4.73x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
10.3%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.62x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.17x

*Line of best fit is calculated by linear regression .

DB:VM4 PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 4.73x ÷ 10.3%

0.46x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Vanda Pharmaceuticals is good value based on expected growth next year.
Price based on value of assets
What value do investors place on Vanda Pharmaceuticals's assets?
Raw Data
DB:VM4 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $7.67
NasdaqGM:VNDA Share Price * NasdaqGM (2020-04-03) in USD $10.29
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.33x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.44x
DB:VM4 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:VNDA Share Price ÷ Book Value per Share (both in USD)

= 10.29 ÷ 7.67

1.34x

* Primary Listing of Vanda Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Vanda Pharmaceuticals is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Vanda Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Vanda Pharmaceuticals has a total score of 6/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Vanda Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
10.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Vanda Pharmaceuticals expected to grow at an attractive rate?
  • Vanda Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • Vanda Pharmaceuticals's earnings growth is positive but not above the Germany market average.
  • Vanda Pharmaceuticals's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:VM4 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:VM4 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 10.3%
DB:VM4 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts 10.2%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 55.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 24%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:VM4 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:VM4 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 376 108 2
2023-12-31 345 84 2
2022-12-31 310 55 2
2021-12-31 262 31 4
2020-12-31 248 17 4
2020-04-05
DB:VM4 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 227 46 116
2019-09-30 219 51 122
2019-06-30 209 54 28
2019-03-31 197 38 22
2018-12-31 193 30 25
2018-09-30 184 18 13
2018-06-30 177 12 1
2018-03-31 171 5 -5
2017-12-31 165 -2 -16
2017-09-30 159 -7 -14
2017-06-30 156 -8 -10
2017-03-31 150 -9 -13

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Vanda Pharmaceuticals's earnings are expected to grow by 10.3% yearly, however this is not considered high growth (20% yearly).
  • Vanda Pharmaceuticals's revenue is expected to grow by 10.2% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:VM4 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Vanda Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:VM4 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 1.83 2.06 1.60 2.00
2023-12-31 1.43 1.69 1.16 2.00
2022-12-31 0.82 1.25 0.56 3.00
2021-12-31 0.28 0.64 -0.34 4.00
2020-12-31 0.29 0.39 0.18 4.00
2020-04-05
DB:VM4 Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 2.17
2019-09-30 2.30
2019-06-30 0.54
2019-03-31 0.41
2018-12-31 0.50
2018-09-30 0.27
2018-06-30 0.03
2018-03-31 -0.11
2017-12-31 -0.35
2017-09-30 -0.32
2017-06-30 -0.23
2017-03-31 -0.30

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Vanda Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Vanda Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Vanda Pharmaceuticals has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Vanda Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Vanda Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Vanda Pharmaceuticals has delivered over 20% year on year earnings growth in the past 5 years.
  • Vanda Pharmaceuticals's 1-year earnings growth exceeds its 5-year average (358.4% vs 35%)
  • Vanda Pharmaceuticals's earnings growth has exceeded the Europe Biotechs industry average in the past year (358.4% vs 16.1%).
Earnings and Revenue History
Vanda Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Vanda Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:VM4 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 227.19 115.55 129.74 48.65
2019-09-30 219.30 121.70 117.64 48.50
2019-06-30 208.95 28.45 113.47 48.54
2019-03-31 197.24 21.53 109.96 47.46
2018-12-31 193.12 25.21 105.75 43.59
2018-09-30 184.35 13.01 111.88 40.83
2018-06-30 176.55 1.29 116.96 39.61
2018-03-31 171.26 -4.86 120.37 37.40
2017-12-31 165.08 -15.57 123.84 38.55
2017-09-30 159.05 -14.33 116.70 36.01
2017-06-30 156.20 -10.21 107.48 33.12
2017-03-31 150.17 -13.30 100.79 32.18
2016-12-31 146.02 -18.01 99.79 29.16
2016-09-30 139.62 -32.20 104.76 30.29
2016-06-30 129.48 -41.23 101.31 32.97
2016-03-31 121.04 -42.00 95.02 32.22
2015-12-31 109.93 -39.87 84.53 29.15
2015-09-30 93.45 44.65 72.97 25.15
2015-06-30 79.88 52.69 65.80 18.88
2015-03-31 63.16 36.50 75.56 16.45
2014-12-31 50.16 20.19 84.64 19.23
2014-09-30 43.57 -57.28 77.25 20.75
2014-06-30 37.50 -61.26 71.70 25.07
2014-03-31 34.95 -43.07 48.82 27.65
2013-12-31 33.88 -21.06 25.08 28.50
2013-09-30 33.02 -19.68 17.84 33.39
2013-06-30 32.60 -19.60 15.36 35.41

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Vanda Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
  • Vanda Pharmaceuticals used its assets more efficiently than the Europe Biotechs industry average last year based on Return on Assets.
  • Vanda Pharmaceuticals has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).
X
Past performance checks
We assess Vanda Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Vanda Pharmaceuticals has a total score of 6/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Vanda Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Vanda Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Vanda Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Vanda Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Vanda Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Vanda Pharmaceuticals has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Vanda Pharmaceuticals Company Filings, last reported 3 months ago.

DB:VM4 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 410.95 0.00 312.13
2019-09-30 400.91 0.00 237.79
2019-06-30 296.69 0.00 280.16
2019-03-31 278.41 0.00 267.84
2018-12-31 275.42 0.00 257.36
2018-09-30 261.42 0.00 240.58
2018-06-30 251.27 0.00 231.22
2018-03-31 241.14 0.00 248.83
2017-12-31 131.39 0.00 143.41
2017-09-30 130.47 0.00 139.88
2017-06-30 131.42 0.00 137.12
2017-03-31 128.14 0.00 137.76
2016-12-31 131.33 0.00 141.34
2016-09-30 129.17 0.00 142.58
2016-06-30 121.61 0.00 135.99
2016-03-31 123.01 0.00 138.33
2015-12-31 133.03 0.00 143.18
2015-09-30 145.94 0.00 144.32
2015-06-30 149.75 0.00 146.64
2015-03-31 152.47 0.00 134.33
2014-12-31 160.82 0.00 129.82
2014-09-30 1.06 0.00 56.09
2014-06-30 0.89 0.00 63.59
2014-03-31 20.98 0.00 100.40
2013-12-31 44.12 0.00 130.35
2013-09-30 50.00 0.00 142.17
2013-06-30 5.03 0.00 103.63
  • Vanda Pharmaceuticals has no debt.
  • Vanda Pharmaceuticals has not taken on any debt in the past 5 years.
  • Vanda Pharmaceuticals has no debt, it does not need to be covered by operating cash flow.
  • Vanda Pharmaceuticals has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess Vanda Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Vanda Pharmaceuticals has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Vanda Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Vanda Pharmaceuticals dividends. Estimated to be 0% next year.
If you bought €2,000 of Vanda Pharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Vanda Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Vanda Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:VM4 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 316 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:VM4 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31 0.00 1.00
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2020-04-05

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Vanda Pharmaceuticals has not reported any payouts.
  • Unable to verify if Vanda Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Vanda Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Vanda Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Vanda Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Vanda Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Vanda Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Vanda Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Vanda Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Mihael Polymeropoulos
COMPENSATION $4,284,676
AGE 59
TENURE AS CEO 16.9 years
CEO Bio

Dr. Mihael H. Polymeropoulos, M.D. founded Vanda Pharmaceuticals, Inc. in 2003 and has been its Chief Executive Officer, President and Director since May, 2003. Dr. Polymeropoulos has also been the Chief Financial Officer at Vanda Pharmaceuticals, Inc. since August 6, 2010 and served as its Principal Accounting Officer since August 6, 2010. He served as Vice President and Head of the Pharmacogenetics Department at Novartis Pharmaceuticals Corporation (Maryland) from 1998 to 2003. He served as the Chief of the Gene Mapping Section, Laboratory of Genetic Disease Research, NHGRI from 1992 to 1998. Dr. Polymeropoulos is the co-founder of the Integrated Molecular Analysis of Genome Expression (IMAGE) Consortium. He has published extensively on the subject of human genetics. Dr. Polymeropoulos holds a degree in Medicine from the University of Patras.

CEO Compensation
  • Mihael's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Mihael's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Vanda Pharmaceuticals management team in years:

0.7
Average Tenure
50
Average Age
  • The average tenure for the Vanda Pharmaceuticals management team is less than 2 years, this suggests a new team.
Management Team

Mihael Polymeropoulos

TITLE
Founder
COMPENSATION
$4M
AGE
59
TENURE
16.9 yrs

Tim Williams

TITLE
Senior VP
COMPENSATION
$3M
TENURE
1.7 yrs

Gunther Birznieks

TITLE
Senior Vice President of Business Development
COMPENSATION
$2M
AGE
50
TENURE
3.1 yrs

Kevin Moran

TITLE
Acting CFO
AGE
35
TENURE
0.1 yrs

AJ Jones

TITLE
Chief Corporate Affairs & Communications Officer
TENURE
0.7 yrs

Kim Wijkstrom

TITLE
Chief Marketing Officer
TENURE
0.7 yrs

Scott Howell

TITLE
Chief People Officer
TENURE
0.7 yrs

Elizabeth Van Every

TITLE
Head of Corporate Affairs
Board of Directors Tenure

Average tenure and age of the Vanda Pharmaceuticals board of directors in years:

3.5
Average Tenure
62.5
Average Age
  • The tenure for the Vanda Pharmaceuticals board of directors is about average.
Board of Directors

Tom Watkins

TITLE
Independent Chairman of the Board
COMPENSATION
$282K
AGE
66
TENURE
6.1 yrs

Mihael Polymeropoulos

TITLE
Founder
COMPENSATION
$4M
AGE
59
TENURE
16.9 yrs

Richard Dugan

TITLE
Independent Director
COMPENSATION
$264K
AGE
77
TENURE
14.3 yrs

Phaedra Chrousos

TITLE
Director
AGE
39
TENURE
1 yrs

Anne Ward

TITLE
Director
AGE
47
TENURE
0.5 yrs

Stephen Mitchell

TITLE
Independent Director
AGE
67
TENURE
0.2 yrs
Who owns this company?
Recent Insider Trading
  • Vanda Pharmaceuticals individual insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
04. Mar 20 Sell Gian Reverberi Individual 02. Mar 20 02. Mar 20 -1,450 €9.13 €-13,235
04. Mar 20 Sell Gunther Birznieks Individual 02. Mar 20 03. Mar 20 -17,758 €9.56 €-162,904
04. Mar 20 Sell Mihael Polymeropoulos Individual 02. Mar 20 03. Mar 20 -15,580 €9.84 €-149,530
04. Mar 20 Sell James Kelly Individual 02. Mar 20 03. Mar 20 -18,857 €9.65 €-175,256
04. Mar 20 Sell Timothy Williams Individual 02. Mar 20 03. Mar 20 -4,385 €9.43 €-40,746
06. Jan 20 Sell Gian Reverberi Individual 02. Jan 20 02. Jan 20 -1,155 €14.36 €-16,586
06. Jan 20 Sell Mihael Polymeropoulos Individual 02. Jan 20 02. Jan 20 -9,467 €14.31 €-135,450
06. Jan 20 Sell James Kelly Individual 02. Jan 20 02. Jan 20 -4,020 €14.25 €-57,299
06. Jan 20 Sell Gunther Birznieks Individual 02. Jan 20 02. Jan 20 -4,020 €14.24 €-57,241
15. Aug 19 Sell Timothy Williams Individual 14. Aug 19 14. Aug 19 -2,575 €13.18 €-33,948
X
Management checks
We assess Vanda Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Vanda Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address unmet medical needs and improve the lives of patients. The company’s marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia. Its products also include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is in phase-III clinical trials for the treatment of atopic dermatitis, gastroparesis, and motion sickness; VTR-297, a small molecule histone deacetylase inhibitor, which is in phase II clinical trials for the treatment of hematologic malignancies; and VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist, for the treatment of psychiatric disorders. In addition, the company is developing cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as secretory diarrhea disorders, including cholera. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Details
Name: Vanda Pharmaceuticals Inc.
VM4
Exchange: DB
Founded: 2002
$510,695,294
53,648,617
Website: http://www.vandapharma.com
Address: Vanda Pharmaceuticals Inc.
2200 Pennsylvania Avenue NW,
Suite 300E,
Washington,
District Of Columbia, 20037,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM VNDA Common Stock Nasdaq Global Market US USD 12. Apr 2006
DB VM4 Common Stock Deutsche Boerse AG DE EUR 12. Apr 2006
LSE 0LKB Common Stock London Stock Exchange GB USD 12. Apr 2006
BRSE VM4 Common Stock Berne Stock Exchange CH CHF 12. Apr 2006
Number of employees
Current staff
Staff numbers
284
Vanda Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/05 22:17
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2020/03/25
Last earnings filing: 2020/02/26
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.